Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

about

Novel drug delivery systems, devices, and fabrication methods.

P2860

Q50075767-57D440BD-EFE0-4AFB-BD5E-10D9B6232306

P2860

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

Item

http://www.wikidata.org/entity/Q47684318

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

@en

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

@nl

type

Item

label

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

@en

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

@nl

prefLabel

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

@en

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

@nl

P1476

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

@en

P2093

Alexander Schwarz

http://www.w3.org/2001/XMLSchema#string

Jari Mikkola

http://www.w3.org/2001/XMLSchema#string

Lasse Leino

http://www.w3.org/2001/XMLSchema#string

Mika Koskinen

http://www.w3.org/2001/XMLSchema#string

Puneet Tyagi

http://www.w3.org/2001/XMLSchema#string

P2860

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Clinical pharmacokinetics of therapeutic monoclonal antibodies.

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway.

Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues.

Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

A strategy for risk mitigation of antibodies with fast clearance.

Injectability of biodegradable in situ forming microparticle systems (ISM).

Protein-polyanion interactions for the controlled release of monoclonal antibodies.

Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation.

P2888

s13346-017-0408-1

P31

scholarly article

P356

10.1007/S13346-017-0408-1

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28752299

http://www.w3.org/2001/XMLSchema#string

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

about

P2860

P2860

Silica microparticles for sustained zero-order release of an anti-CD40L antibody.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698